Dedalus illustrated its plans for the future and gave its partners the chance to explain the synergy targeted by the partnership.

Keenturtle has already been able to achieve decisive results against DxCare, Orbis and DopaSys, in terms of drug risk detection; a detection and reduction potential that only PharmaClass® can currently guarantee in all current heterogeneous IT contexts. This event was an opportunity for Keenturtle to announce even higher levels of results, which will be possible thanks to the partnership with Dedalus.

The iatrogenic numbers had remained near-constant, and high, for decades; a first level has been reached, a second is within reach, for the benefit of patients, healthcare professionals… and as we underlined in the session, CIOs!

Thanks to Dedalus for your trust and a big congratulations for this incredible organization.